Abstract
IntroductionIn ADAPT, efgartigimod, a human IgG1 antibody Fc-fragment blocking neonatal Fc receptor, resulted in clinically meaningful improvement (CMI) in myasthenia gravis (MG)-specific measures. Patients completing ADAPT were eligible to enrol...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have